Citius Pharmaceuticals (CTXR) Competitors $0.20 -0.13 (-39.39%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends CTXR vs. VTGN, DARE, PTI, MACK, CMPS, SAGE, YSB, RZLT, ITOS, and STROShould you be buying Citius Pharmaceuticals stock or one of its competitors? The main competitors of Citius Pharmaceuticals include Vistagen Therapeutics (VTGN), Daré Bioscience (DARE), Proteostasis Therapeutics (PTI), Merrimack Pharmaceuticals (MACK), COMPASS Pathways (CMPS), Sage Therapeutics (SAGE), YS Biopharma (YSB), Rezolute (RZLT), iTeos Therapeutics (ITOS), and Sutro Biopharma (STRO). These companies are all part of the "medical" sector. Citius Pharmaceuticals vs. Vistagen Therapeutics Daré Bioscience Proteostasis Therapeutics Merrimack Pharmaceuticals COMPASS Pathways Sage Therapeutics YS Biopharma Rezolute iTeos Therapeutics Sutro Biopharma Vistagen Therapeutics (NASDAQ:VTGN) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, community ranking, analyst recommendations, earnings and valuation. Do analysts prefer VTGN or CTXR? Vistagen Therapeutics currently has a consensus price target of $15.00, suggesting a potential upside of 470.34%. Citius Pharmaceuticals has a consensus price target of $4.00, suggesting a potential upside of 1,900.00%. Given Citius Pharmaceuticals' higher probable upside, analysts clearly believe Citius Pharmaceuticals is more favorable than Vistagen Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vistagen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Citius Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Does the media favor VTGN or CTXR? In the previous week, Citius Pharmaceuticals had 9 more articles in the media than Vistagen Therapeutics. MarketBeat recorded 17 mentions for Citius Pharmaceuticals and 8 mentions for Vistagen Therapeutics. Vistagen Therapeutics' average media sentiment score of 1.35 beat Citius Pharmaceuticals' score of 0.59 indicating that Vistagen Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vistagen Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Citius Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings & valuation, VTGN or CTXR? Vistagen Therapeutics has higher revenue and earnings than Citius Pharmaceuticals. Vistagen Therapeutics is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVistagen Therapeutics$1.06M69.07-$29.36M-$1.24-2.12Citius PharmaceuticalsN/AN/A-$32.54M-$0.24-0.83 Is VTGN or CTXR more profitable? Citius Pharmaceuticals has a net margin of 0.00% compared to Vistagen Therapeutics' net margin of -4,521.71%. Vistagen Therapeutics' return on equity of -36.35% beat Citius Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Vistagen Therapeutics-4,521.71% -36.35% -33.62% Citius Pharmaceuticals N/A -44.65%-39.39% Do institutionals and insiders hold more shares of VTGN or CTXR? 78.4% of Vistagen Therapeutics shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 1.3% of Vistagen Therapeutics shares are held by insiders. Comparatively, 15.0% of Citius Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more risk & volatility, VTGN or CTXR? Vistagen Therapeutics has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500. Does the MarketBeat Community prefer VTGN or CTXR? Vistagen Therapeutics received 73 more outperform votes than Citius Pharmaceuticals when rated by MarketBeat users. Likewise, 72.31% of users gave Vistagen Therapeutics an outperform vote while only 62.39% of users gave Citius Pharmaceuticals an outperform vote. CompanyUnderperformOutperformVistagen TherapeuticsOutperform Votes28272.31% Underperform Votes10827.69% Citius PharmaceuticalsOutperform Votes20962.39% Underperform Votes12637.61% SummaryVistagen Therapeutics beats Citius Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Ad WealthPressHow one pattern has averaged an 85% return per year since the pandemic. Over the last 5 years Roger Scott has done some pretty incredible things… He’s found hundreds of winning opportunities… He’s created some incredible strategies… And he’s even designed some amazing tools… But there is one thing he’s always kept close to the chest… And in this case, it’s been a very particular stock market pattern…. A pattern he calls the World's Most Predictable Pattern…Follow this link here and enter your email address to sign up… Get Citius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTXR vs. The Competition Export to ExcelMetricCitius PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.15M$6.53B$5.15B$8.74BDividend YieldN/A8.15%5.18%4.08%P/E Ratio-0.834.4062.6013.00Price / SalesN/A377.651,277.9088.72Price / CashN/A51.2139.7935.27Price / Book0.349.636.455.92Net Income-$32.54M$154.43M$119.73M$225.73M7 Day Performance-51.40%-9.46%-5.13%-1.34%1 Month Performance-51.22%-7.27%-2.71%1.15%1 Year Performance-74.12%28.13%31.08%24.02% Citius Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTXRCitius Pharmaceuticals3.0338 of 5 stars$0.20-39.4%$4.00+1,900.0%-73.8%$36.15MN/A-0.8320Analyst ForecastShort Interest ↓Analyst RevisionNews CoverageGap DownHigh Trading VolumeVTGNVistagen Therapeutics3.8962 of 5 stars$2.95+0.7%N/A-20.8%$82.13M$1.06M-2.3840Short Interest ↓Positive NewsDAREDaré Bioscience2.101 of 5 stars$4.69+6.3%N/A-20.1%$40.08M$2.84M-4.1830Analyst ForecastShort Interest ↓News CoveragePTIProteostasis TherapeuticsN/AN/AN/AN/A$37.57M$5M-0.6244Gap UpMACKMerrimack PharmaceuticalsN/A$15.13flatN/AN/A$223.77MN/A1.09426Analyst ForecastCMPSCOMPASS Pathways3.0359 of 5 stars$5.14+1.8%N/A-11.0%$351.68MN/A-2.34120Short Interest ↓Gap UpSAGESage Therapeutics4.4458 of 5 stars$5.71-0.3%N/A-72.6%$349.28M$86.46M-1.02690YSBYS BiopharmaN/AN/AN/AN/A$344.32M$560.76M0.00773RZLTRezolute4.2541 of 5 stars$5.82-2.3%N/A+554.3%$337.21MN/A-4.5840Positive NewsITOSiTeos Therapeutics3.0713 of 5 stars$9.19-2.0%N/A-15.9%$335.62M$12.60M-3.0690Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews CoverageSTROSutro Biopharma4.3748 of 5 stars$4.08-7.3%N/A+23.0%$334.40M$153.73M-2.23240Analyst RevisionNews Coverage Related Companies and Tools Related Companies VTGN Competitors DARE Competitors PTI Competitors MACK Competitors CMPS Competitors SAGE Competitors YSB Competitors RZLT Competitors ITOS Competitors STRO Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CTXR) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
